Myrobalan Therapeutics is a preclinical-stage biotechnology company headquartered in Medford, Massachusetts, focused on developing orally bioavailable, brain-penetrant small-molecule therapies to restore brain function. The company targets key pathologies underlying CNS dysfunction, including demyelination and neuroinflammation, applying expertise in drug discovery and neurological processes. Its lead program, MRO-002, is a small-molecule antagonist of GPR17 designed to remove a block to myelin repair. Myrobalan is developing MRO-002 specifically for progressive multiple sclerosis with the goal of promoting remyelination. The company says its candidates are positioned to treat neurodegenerative diseases, demyelinating disorders, and conditions involving recovery from CNS injury. Recent grant support from the National Multiple Sclerosis Society will advance the program's preclinical and translational development. Myrobalan Therapeutics is a preclinical-stage biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unmet-need central nervous system (CNS) conditions. Its pipeline focuses on brain-penetrant remyelination and anti-neuroinflammation programs, including a lead CSF1R inhibitor program and a demyelination-targeting GPR17 program. The company applies deep knowledge of neurological processes and innovative drug discovery tools to create highly selective, brain-penetrant therapeutic candidates. Myrobalan completed a subsequent closing of its Series A, adding $9 million and bringing total Series A funding to $33 million. The new capital is intended to advance the CSF1R program through first-in-human clinical testing and to progress the GPR17 program through IND-enabling studies. The company is headquartered in Medford, Massachusetts and is advancing its pipeline with strategic support from renowned institutional co‑founders. Myrobalan develops orally available small‑molecule neurorestorative therapies targeting demyelination and neuroinflammation to restore neural function in high‑unmet‑need CNS diseases. Its lead programs include a GPR17 antagonist to promote remyelination, a CSF1R inhibitor to address demyelination and neuroinflammation, and an allosteric TYK2 inhibitor to reduce neuroinflammation. The company applies brain‑penetrant, highly selective chemistry and strategic drug‑discovery tools to create candidates positioned for chronic, tolerable oral dosing. Myrobalan plans to address a broad range of neurological conditions linked to these mechanisms, including MS, Alzheimer’s disease, ALS, and rare neurological diseases. The company emphasizes strong preclinical data and a strategic chemistry partnership to advance candidates toward the clinic. Myrobalan is headquartered in Medford, Massachusetts, and completed a $24 million Series A to fund advancement of its pipeline.

Total raised

$34M

Funding rounds

3

Latest round

Grant

Latest activity

Mar 2025